The European Medicines Agency (EMA) on April 8, 2026, published a proposal for an enhanced monitoring framework to assess the effectiveness of veterinary medicines in real-world conditions. The document, issued by EMA's Veterinary Medicines Division, recommends systematic post-authorisation studies and data collection to ensure that veterinary products continue to meet safety and efficacy standards after market entry. The proposal targets veterinary pharmaceutical companies, national competent authorities, and livestock producers, who would face new reporting obligations and potential adjustments to product use.
The proposal is a formal opinion under EU pharmaceutical legislation, outlining specific recommendations for monitoring protocols, data standardisation, and reporting timelines. It calls for a shift from passive pharmacovigilance to active surveillance, including the use of electronic health records from veterinary practices and slaughterhouse data. While the framework is non-binding, it is expected to influence future regulatory requirements.
Policy orientations and trade-offs The EMA's proposal emphasises two main policy orientations: increasing real-world evidence collection to detect efficacy failures or resistance patterns early, and harmonising monitoring practices across member states to enable cross-border data comparability. However, the document acknowledges trade-offs: enhanced monitoring could improve animal health outcomes and support prudent use of antimicrobials, aligning with the EU's Farm to Fork Strategy and the 2023 revision of the veterinary medicines regulation. On the other hand, it may impose additional administrative and financial burdens on veterinary medicine holders and national authorities, potentially slowing market access for new products.
Impact on stakeholders For veterinary pharmaceutical companies, the proposal implies increased costs for post-authorisation studies and data infrastructure, potentially affecting smaller firms disproportionately. National competent authorities would need to invest in data management systems and coordinate with EMA, straining resources. Livestock producers and veterinarians may face additional record-keeping requirements, but could benefit from better-informed treatment decisions and reduced risk of product withdrawal. EU consumers and animal welfare groups stand to gain from improved oversight of veterinary medicine effectiveness, supporting food safety and antimicrobial resistance goals.
Expected institutional follow-up EMA's proposal will be open for public consultation before a final opinion is adopted. The European Commission is expected to consider the recommendations in its ongoing evaluation of the veterinary medicines regulatory framework, with potential legislative amendments anticipated by 2027.
← Atlas › News › Agri-food